Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
5-Year IF – 2.0, IF – 1.9, JCI (2024) – 0.43
Scopus CiteScore – 4.3
Q1 in SJR 2024, SJR score – 0.598, H-index: 49 (SJR)
ICV – 161.00; MNiSW – 70 pts
Initial editorial assessment and first decision within 24 h

ISSN 1899–5276 (print), ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2015, vol. 24, nr 5, September-October, p. 815–822

doi: 10.17219/acem/26003

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Fecal Calprotectin as an Activity Marker of Inflammatory Bowel Disease in Children

Elżbieta Krzesiek1,

1 nd Department and Clinic of Paediatrics, Gastroenterology and Nutrition, Wroclaw Medical University, Poland

Abstract

Background. Children constitute 20% of patients with inflammatory bowel diseases (IBD). Still there is a search for a perfect marker for this group of patients which would help in the diagnosis of the disease, in determinating its activity and in monitoring the treatment.
Objectives. Evaluate the usefulness of the application of calprotectin measurement in stool samples from children with IBD, as a marker of the severity of inflammation.
Material and Methods. We analysed 156 patients: 58 with ulcerative colitis (UC), 67 with Crohn’s disease (CD), and 31 from the control group. In all patients the concentration of calprotectin in the sample of feces, markers of inflammation and hemoglobin were measured.
Results. Concentration of calprotectin in feces of patients with IBD was above the normal range in all patients with moderate and severe disease and in the majority with mild disease or in remission, but it was normal in all patients from the control group.
Conclusion. Elevated concentration of fecal calprotectin (FC) was observed in the majority of patients with IBD, but in none from the control group. The number of patients with elevated FC concentration increased together with the disease activity. FC concentration was higher in patients with severe and moderate disease activity. FC concentration in patients with IBD was associated with the increase of inflammatory markers and decreased haemoglobin. Percentage of laboratory abnormalities in children with Crohn’s disease and perianal changes was higher. FC concentration can be a noninvasive marker of disease activity in IBD.

Key words

inflammatory bowel disease, children, calprotectin

References (32)

  1. Inflammatory bowel disease in children and adolescents: recommendation for diagnosis – the Porto criteria. JPGN 2005, 41, 1–7.
  2. Kobielska-Dubiel N, Ignyś I, Krauss H: Fecal calprotectin as an inflammatory marker in inflammatory bowel diseases. Pediatr Współcz Gastroenterol Hepatol Żyw Dziecka 2007, 9, 3, 172–175.
  3. Kosiara M, Paradowski L: Calprotectin. Gastroenterol Pol 2008, 15, 5, 333–335.
  4. Hyams JS, Ferry GD, Mandel FS: Development and validation of a pediatric Crohn’s disease activity index. Pediatr Gastroenterol Nutr 1991, 12, 439–447
  5. Turner D, Otley AR, Mack D: Development, validation, and evaluation of a pediatric ulcerative colitis activity index. Gastroenterology 2007, 133, 423–432.
  6. Szachta P, Roszak D, Gałecka M: Nonivasive markers in inflammatory bowel disease. Gastroenterol Pol 2009, 16, 5, 399–401.
  7. Vermeire S, Van Assche G, Rutgeerts P: Laboratory markers In IBD: useful, magic, or unnecessary toys? Gut 2006, 55, 426–431.
  8. Lisowska-Myjak B, Walo M, Pachecka J: Endogenous proteins measured in the faeces as laboratory markers for diagnosis, differentiation and intensity evaluation of inllammatory bowel disease. Gastroenterol Pol 2007, 14, 5, 357–361.
  9. Rodrigo L: Fecal calprotectin. Rev Esp Enferm Dig 2007, 99, 12, 683–688.
  10. Ślemp-Migiel A, Wiczkowski A: Human endogenous antibacterial proteins and peptides. Ann Acad Med Siles 2006, 60, 4, 366–369.
  11. Tomas AB, Vidal MV, Camps AR: Fecal calprotectin as a biomarker to distinguish between organic and functional gastrointestinal disease. Rev Esp Enferm Dig 2007, 99, 12, 689–693.
  12. Walkiewicz D, Werlin SL, Fish D: Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2008, 14, 5, 669–673.
  13. Sipponen T, Savilahti E, Karkkainen P: Fecal calprotectin, lactoferin and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn’s disease. Inflamm Bowel Dis 2008, 14, 10, 1392–1398.
  14. Kosiara M, Paradowski LA: New tool to describe inflammatory bowel disease activity? Gastroenterol Pol 2009, 16, 6, 436–439.
  15. Quail MA, Russel RK, Van Limbergen JE: Fecal calprotectin complements routine laboratory investigations in diagnosing childhood inflammatory bowel disease. Inflamm Bowel Dis 2009, 15, 5, 756–759.
  16. Konikoff MR, Denson LA: Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease. Inflamm Bowel Dis 2006, 12, 6, 524–534.
  17. Vieira V, Fang Ch B, Rolim EG: Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferin: correlation with laboratory parameters, clinical, endoscopic and histological indexes. BMC Res Not 2009, 2, 221.
  18. Wagner M, Peterson Ch, Ridefelt P: Fecal markers of inflammation used as surrogate markers for treatement outcome in relapsing inflammatory bowel disease. World J Gastroenterol 2008, 14, 36, 5584–5589.
  19. Sipponen T, Savilahti E, Kohlo KL: Cronn’s disease activity assessed by fecal calprotectin and lactoferin: correlation with Crohn’s disease activity index and endoscopic findings. Inflamm Bowel Dis 2008, 14, 1, 40–46.
  20. Roseth AG, Aadland E, Grzyb K: Normalization of fecal calprotectin: a predictor of mucosal healing in patients with inflammatory bowel disease. Scand J Gastroenterol 2004, 39, 1017–1020.
  21. Smith LA, Gaya DR: Utility of fecal calprotectin analysis in adult inflammatory bowel disease. World J Gastroenterol 2012, 14, 18, 6782–6789.
  22. Schoepfer AM, Beglinger Ch, Straumann A: Fecal calprotectin correlates more closely with the simple endoscopic score for Crohn’s disease (SES-SD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010, 105, 162–169.
  23. Costa F, Mumolo MG, Cecarelli L: Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease. Gut 2005, 54, 364–368.
  24. Gaya DR, Lyon TDB., Duncan A: Fecal calprotectin in the assessement of Crohn’s disease activity. Q J Med 2005, 98, 435–441.
  25. Gisbert JP, McNichol AG: Questions and answers on the role of fecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis 2009, 41, 56–66.
  26. Canani B, Terrin G, Rapacciuolo L: Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig Liver Dis 2008, 40, 547–553.
  27. Komraus M, Woś H, Więcek S: Usefulness of fecal calprotectin measurement in children with various types of inflammatory bowel disease. Mediators of Inflammation 2012, Art ID 608249, 5 pages.
  28. Shaoul R, Sladek M, Turner D: Limitations of fecal calprotectin at diagnosis in untreated pediatric Crohn’s Disease. Inflamm Bowel Dis, 2012, 18, 8, 1493–1497.
  29. Erbayrak M, Turcay C, Eraslan E: The role of fecal calprotectin in investigating inflammatory bowel diseases. Clinics 2009, 64, 5, 421–425.
  30. Eder P, Stawczyk-Eder K, Krela-Kaźmierczak I: Clinical utility of the assessment of fecal calprotectin in Leśniowski-Crohn’s disease. Pol Arch Med Wewn 2008, 118, 11, 622–626.
  31. Schoepfer AM, Trummler M, Seeholzer P: Discriminating IBD from IBS: Comparison of the test performance of fecal markers, blood leukocytes, CRP and IBD antibodies. Inflamm Bowel Dis 2008, 14, 1, 32–39.
  32. Xiang JY, Ouang Q, Li GD: Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis. World J Gastroenterol 2008, 7, 14, 53–57.
© Wroclaw Medical University